BioStem Technologies Inc(BSEM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 4 at 7:30 PM ET (Korea 9/5 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.68 | Insider Own | 28.71% | Shs Outstand | 17.8M | Perf Week | 5.1% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | 45.26% | Insider Trans | - | Shs Float | 12.7M | Perf Month | -7.71% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.43 | Inst Own | - | Short Float | 4.36% | Perf Quarter | -4.77% |
| Income | -0.03B | P/S | 1.91 | EPS this Y | -387.18% | Inst Trans | - | Short Ratio | 7.63 | Perf Half Y | -28.79% |
| Sales | 0.03B | P/B | 2.39 | EPS next 5Y | 38.66% | ROA | -35.05% | Short Interest | 0.55M | Perf YTD | -2.62% |
| Book/sh | 1.55 | P/C | 9.51 | EPS past 3/5Y | 14.56% -7.36% | ROE | -74.74% | 52W High | -55.83% ($8.40) | Perf Year | -44.75% |
| Cash/sh | 0.39 | P/FCF | - | Sales past 3/5Y | 90.44% 81.44% | ROIC | -102.44% | 52W Low | 64.82% ($2.25) | Perf 3Y | 108.43% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -204.26% | Gross Margin | 76.08% | Volatility(W/M) | 9.27% 13.75% | Perf 5Y | 196.8% |
| Dividend TTM | - | EV/Sales | 1.75 | Sales Y/Y TTM | -88.74% | Oper. Margin | -67.47% | ATR (14) | 0.39 | Perf 10Y | -71.46% |
| Dividend Ex-Date | - | Quick Ratio | 0.76 | EPS Q/Q | -1431.95% | Profit Margin | -81.8% | RSI (14) | 52.4 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.98 | Sales Q/Q | -83.98% | SMA20 | 4.47% ($3.55) | Beta | 0.48 | Target Price | $7 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/12 | SMA50 | 3.92% ($3.57) | Rel Volume | 1.2 | Prev Close | $3.61 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | -4% 24.36% | SMA200 | -16.65% ($4.45) | Avg Volume(3M) | 0.07M | Price | $3.71 |
| IPO | 2003/10/17 | Option/Short | No/Yes | Trades | 493 | Volume | 87,415 | Change | 2.77% |
Company
BSEM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US-based life sciences company that develops and manufactures regenerative medicine products derived from placental tissue. It supplies allograft implants—produced using its proprietary processing technology—to the chronic wound care market, and has steadily expanded its applications into tissue regeneration areas where healing tends to be slow, including damage to joints, tendons, and ligaments.
Over the past 1 year, on the lower side
56% below its 1-year high.
BSEM has weak earning power
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -387.2% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +108.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 28.7%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $66M.
BSEM $66M PER -
VRTX $138B PER 31.8
REGN $85B PER 20.5
ARGX $65B PER 39.4
FAQ
What kind of company is BSEM?
BSEM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BSEM?
The market cap of BSEM is approximately $66M, ranking 4,836 within its sector.
What is the 52-week high and low for BSEM?
BSEM has recorded a 52-week high of $8.40 and a low of $2.25.
